[
  {
    "ts": "2026-02-03T02:10:09+00:00",
    "headline": "ERLEADA And DARZALEX FASPRO Updates Shape Johnson And Johnson Oncology Story",
    "summary": "New clinical data supports ERLEADA for metastatic castration sensitive prostate cancer, reinforcing its role in current treatment practice. DARZALEX FASPRO received expanded FDA approval for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplant. These updates reflect further development in Johnson & Johnson's oncology portfolio under ticker NYSE:JNJ. For investors tracking NYSE:JNJ, these oncology updates come as the stock trades around $230.75, with a...",
    "url": "https://finance.yahoo.com/news/erleada-darzalex-faspro-updates-shape-021009894.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "72430741-6f88-3672-9ddf-32d797d2f9d5",
      "content": {
        "id": "72430741-6f88-3672-9ddf-32d797d2f9d5",
        "contentType": "STORY",
        "title": "ERLEADA And DARZALEX FASPRO Updates Shape Johnson And Johnson Oncology Story",
        "description": "",
        "summary": "New clinical data supports ERLEADA for metastatic castration sensitive prostate cancer, reinforcing its role in current treatment practice. DARZALEX FASPRO received expanded FDA approval for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplant. These updates reflect further development in Johnson & Johnson's oncology portfolio under ticker NYSE:JNJ. For investors tracking NYSE:JNJ, these oncology updates come as the stock trades around $230.75, with a...",
        "pubDate": "2026-02-03T02:10:09Z",
        "displayTime": "2026-02-03T02:10:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmOStVnJjLnU3xikg4stLA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trESudVvS0UypUeXuQ_Yww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/erleada-darzalex-faspro-updates-shape-021009894.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/erleada-darzalex-faspro-updates-shape-021009894.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]